Thermo Fisher Scientific, the world leader in serving science, is adding early development work for oral solid dose therapies to its Bourgoin, France site,...
The project will see the site’s footprint increase by 32,000 square feet (3,000 square meters) to add capacity for the storage and handling of clinic...
Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune ...
Both presentations are from the company’s CORAL program, which is evaluating various self-amplifying mRNA (samRNA) vaccine candidates targeting Spike...
-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023- -Vertex Pharmac...
The funds will be mainly used to develop lead program Levodopa Cyclops™ for US and EEA marketing, of which early clinical studies already demonstrate...
Galapagos to transfer drug discovery and research activities in Romainville, France to NovAliX, a drug-discovery focused Contract Research Organization (...
Medtronic plc (NYSE: MDT) and DaVita Inc. (NYSE: DVA) announced the launch of Mozarc Medical—an independent new company committed to reshap...
Ideal for the transportation of life-saving pharmaceutical, biotech and life-science products, Tower’s robust, reliable, reusable solutions are a wel...
Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD) Modulation of neuroinflammati...
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assay...
Today, NEC and NOI announced that NOI will be realigned as a subsidiary of NEC Bio B.V. (NB) in Hilversum, Netherlands, a newly established wholly owned su...
On 23 January 2023, the acceptance period during which DSM Shareholders can tender their DSM Ordinary Shares into the Exchange Offer was extended as not al...
Søren Tulstrup, President and CEO, Hansa Biopharma said, "This phase 2 study of imlifidase in GBS is an important next step in understanding the rol...
© 2024 Biopharma Boardroom. All Rights Reserved.
